CapsoVision, Inc — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
CapsoVision appointed David S. Shields, M.D., a board-certified gastroenterologist with 40+ years experience, to its Board of Directors effective July 1, 2026, succeeding Joanne C. Imperial, M.D. Concurrent with the board transition, the company executed two new consulting agreements: an amended agreement with Dr. Imperial at $600/hour for up to 5 hours/week plus 10,000 stock options vesting 25% after one year then 1/48 monthly; and a new agreement with Dr. Shields at $600/hour for up to 3 hours/week, both for clinical consulting and industrial affiliation services. Dr. Imperial, who served as a clinical advisor since ~2017, will continue as an independent clinical consultant supporting pancreatic cancer and esophageal varices programs.
Why this rating
Board seat swap of consultants; modest ongoing hourly consulting fees (~$156k–$312k annualized at max hours) and option grant (10,000 shares, ~1.5% dilution if fully vested) are immaterial relative to $25.9M asset base. Routine governance transition.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.